Abstract | AIM: PATIENTS AND METHODS: The cohort included 117 men and 81 women with primary glioblastoma multiforme (GBM; n=154), grade III astrocytoma (AA; n=26) and anaplastic oligodendroglioma (AO; n=5). POH inhalation schedule 4-times daily started with 66.7 mg/dose; 266 mg/day and escalated up to 133.4 mg/dose; 533.6 mg/day. Clinical toxicity and overall survival following treatment were compared with tumor size, topography, extent of peritumoral edema and histological classification. RESULTS: Adhesion to the protocol was high (>95%), POH (533.6 mg/daily) occasionally caused nose soreness but rarely nosebleed. Tumor size, peritumoral edema and the oligodendroglial component influenced response to treatment. CONCLUSION: After 4 years under exclusive POH treatment, 19% of patients still remain in clinical remission. Long-term POH inhalation chemotherapy is a safe and non-invasive strategy efficient for recurrent malignant glioma.
|
Authors | Clovis O DA Fonseca, Raphael M Teixeira, Júlio Cesar T Silva, Juliana DE Saldanha DA Gama Fischer, Osório C Meirelles, Jose Alberto Landeiro, Thereza Quirico-Santos |
Journal | Anticancer research
(Anticancer Res)
Vol. 33
Issue 12
Pg. 5625-31
(Dec 2013)
ISSN: 1791-7530 [Electronic] Greece |
PMID | 24324108
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Monoterpenes
- perillyl alcohol
|
Topics |
- Administration, Inhalation
- Adult
- Antineoplastic Agents
(administration & dosage, therapeutic use)
- Brain Neoplasms
(drug therapy)
- Female
- Glioblastoma
(drug therapy)
- Humans
- Magnetic Resonance Imaging
- Male
- Middle Aged
- Monoterpenes
(administration & dosage, therapeutic use)
- Recurrence
- Treatment Outcome
|